{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:56:22Z","timestamp":1793782582399,"version":"4.6.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ygyno.2024.01.032","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T19:26:00Z","timestamp":1706642760000},"page":"57-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations"],"prefix":"10.1016","volume":"184","author":[{"given":"Angela","family":"Santoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Angelico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frediano","family":"Inzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Arciuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"d'Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Addante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Travaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"D'Alessandris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordana","family":"Tinnirello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Raffone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Narducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Piermattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cianfrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Bragantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Franco","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2024.01.032_bb0005","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1364828","article-title":"PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy?","volume":"7","author":"Simon","year":"2017","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14728222.2014.980235","article-title":"The PD-1\/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy","volume":"19","author":"Muenst","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"11","key":"10.1016\/j.ygyno.2024.01.032_bb0015","article-title":"The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment","volume":"21","author":"Hudson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0020","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1515\/mr-2022-0033","article-title":"Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives","volume":"2","author":"Liu","year":"2023","journal-title":"Med. Rev. (Berl.)."},{"issue":"7","key":"10.1016\/j.ygyno.2024.01.032_bb0030","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/jpm12071073","article-title":"Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems","volume":"12","author":"Marletta","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000510812","article-title":"Understanding PD-L1 testing in breast cancer: a practical approach","volume":"15","author":"Erber","year":"2020","journal-title":"Breast Care (Basel)."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.humpath.2020.11.004","article-title":"Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma","volume":"108","author":"Huang","year":"2021","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0045","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41379-021-00882-y","article-title":"Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists","volume":"35","author":"Mills","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115569","article-title":"The therapeutic potential of PD-1\/PD-L1 pathway on immune-related diseases: based on the innate and adaptive immune components","volume":"167","author":"Zhang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0055","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/ijms24020974","article-title":"Application of immune checkpoint inhibitors in gynecological cancers: what do gynecologists need to know before using immune checkpoint inhibitors?","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3390\/cancers14030631","article-title":"Overview of immune checkpoint inhibitors in gynecological cancer treatment","volume":"14","author":"Pir\u0161","year":"2022","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0065","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.3390\/cancers15184632","article-title":"Immune checkpoint inhibitors targeting the PD-1\/PD-L1 pathway in advanced, recurrent endometrial cancer: a scoping review with SWOT analysis","volume":"15","author":"Johnson","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0070","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41379-021-00780-3","article-title":"Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma","volume":"34","author":"Huang","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41379-020-00664-y","article-title":"A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases","volume":"34","author":"Huang","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0080","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1007\/s00432-023-05020-6","article-title":"Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer","volume":"149","author":"Liu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0085","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2021.07.009","article-title":"PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer","volume":"162","author":"Zong","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0090","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.3390\/cancers15164032","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitor as single-agent immunotherapy in endometrial cancer: a systematic review and Meta-analysis","volume":"15","author":"Mamat Yusof","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.795547","article-title":"Immunotherapy in ovarian cancer: thinking beyond PD-1\/PD-L1","volume":"11","author":"Chardin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13048-021-00862-5","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0105","doi-asserted-by":"crossref","first-page":"12067","DOI":"10.3390\/ijms232012067","article-title":"Focus on PD-1\/PD-L1 as a therapeutic target in ovarian cancer","volume":"23","author":"Dumitru","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0110","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.3390\/cancers14163911","article-title":"PD-L1 expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis","volume":"14","author":"Mamat Yusof","year":"2022","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0115","article-title":"Predictive values of programmed cell death-ligand 1 expression for prognosis, clinicopathological factors, and response to programmed cell death-1\/programmed cell death-ligand 1 inhibitors in patients with gynecological cancers: a meta-analysis","volume":"10","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0120","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3390\/cancers15041137","article-title":"Recent advances in cervical cancer management: a review on novel prognostic factors in primary and recurrent tumors","volume":"15","author":"Santoro","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0125","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/apm.13078","article-title":"A possible interplay between HR-HPV and stemness in tumor development: an in vivo investigation of CD133 as a putative marker of cancer stem cell in HPV18-infected KB cell line","volume":"128","author":"de Maria","year":"2020","journal-title":"APMIS."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0130","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0135","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/ijms24020974","article-title":"Application of immune checkpoint inhibitors in gynecological cancers: what do gynecologists need to know before using immune checkpoint inhibitors?","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0140","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/his.14435","article-title":"PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma","volume":"79","author":"Song","year":"2021","journal-title":"Histopathology."},{"issue":"8","key":"10.1016\/j.ygyno.2024.01.032_bb0145","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/PAS.0000000000002058","article-title":"Interobserver agreement on the interpretation of programmed death-ligand 1 (PD-L1) combined positive score (CPS) among gynecologic pathologists","volume":"47","author":"Mills","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0150","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.3390\/cancers15184479","article-title":"Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: a review of current evidence and prognostic implications from pathologist\u2019s perspective","volume":"15","author":"Angelico","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0155","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.jtho.2019.08.2503","article-title":"Impact of specimen characteristics on PD-L1 testing in non-small cell lung cancer: validation of the IASLC PD-L1 testing recommendations","author":"Gagn\u00e9","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0160","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.3390\/cancers13246373","article-title":"The vulvar immunohistochemical panel (VIP) project: molecular profiles of vulvar squamous cell carcinoma","volume":"13","author":"Garganese","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2024.01.032_bb0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ijgo.12609","article-title":"Cancer of the vulva","volume":"143","author":"Rogers","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0170","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s00432-019-02975-3","article-title":"The vulvar immunohistochemical panel (VIP) project: molecular profiles of vulvar Paget\u2019s disease","volume":"145","author":"Garganese","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0175","doi-asserted-by":"crossref","first-page":"92890","DOI":"10.18632\/oncotarget.21641","article-title":"Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology","author":"Hecking","year":"2017","journal-title":"Oncotarget."},{"issue":"52","key":"10.1016\/j.ygyno.2024.01.032_bb0180","doi-asserted-by":"crossref","first-page":"89903","DOI":"10.18632\/oncotarget.20911","article-title":"PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients","volume":"8","author":"Sznurkowski","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.anndiagpath.2019.04.004","article-title":"The predictive and prognostic value of Foxp3+\/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer","volume":"40","author":"Zhang","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/his.13723","article-title":"PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy","volume":"74","author":"Chinn","year":"2019","journal-title":"Histopathology."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0195","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ygyno.2017.05.011","article-title":"Identification of molecular targets in vulvar cancers","volume":"146","author":"Palisoul","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0200","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2022.01.029","article-title":"Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study","volume":"166","author":"Shapira-Frommer","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0205","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/jcm11041101","article-title":"Immunotherapeutic approaches for the treatment of HPV-associated (pre-)cancer of the cervix, vulva and penis","volume":"11","author":"Rafael","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0210","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.critrevonc.2016.03.008","article-title":"Paget disease of the vulva","volume":"101","author":"van der Linden","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0215","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/cancers11060754","article-title":"Expression of PD-1 and PD-L1 in extramammary Paget disease: implications for immune-targeted therapy","volume":"11","author":"Mauzo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2024.01.032_bb0220","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.18632\/oncotarget.27247","article-title":"Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer\/testis antigens NY-ESO-1 and MAGE-A","volume":"10","author":"Pourmaleki","year":"2019","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0225","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/cancers15061803","article-title":"Vulvar Paget\u2019s disease: a systematic review of the MITO rare cancer group","volume":"15","author":"Caruso","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0230","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/cancers13112623","article-title":"New pathological and clinical insights in endometrial cancer in view of the updated ESGO\/ESTRO\/ESP guidelines","volume":"13","author":"Santoro","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0235","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.3390\/cancers15164032","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitor as single-agent immunotherapy in endometrial cancer: a systematic review and meta-analysis","volume":"15","author":"Mamat Yusof","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0240","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/s41379-022-01131-6","article-title":"Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma","volume":"35","author":"Chen","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0250","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-18-0784","article-title":"Consensus on molecular subtypes of high-grade serous ovarian carcinoma","volume":"24","author":"Chen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0255","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygyno.2023.09.012","article-title":"Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: exploratory analysis of KEYNOTE-100","volume":"178","author":"Ledermann","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0265","article-title":"Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0270","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00428-023-03512-x","article-title":"Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8+tumor-infiltrating lymphocytes and patient prognosis","volume":"482","author":"Zhang","year":"2023","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0275","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0280","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104084","article-title":"Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: a systematic review and meta-analysis","volume":"189","author":"Fu","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2024.01.032_bb0290","doi-asserted-by":"crossref","first-page":"114150","DOI":"10.1016\/j.biopha.2022.114150","article-title":"Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies","volume":"158","author":"Mortezaee","year":"2023","journal-title":"Biomed. Pharmacother."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824000477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824000477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:52:19Z","timestamp":1726246339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824000477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":58,"alternative-id":["S0090825824000477"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.032","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}